Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Ocular hypertension or primary open-angle glaucoma in each eye

• Patient requires IOP lowering medication in each eye

Exclusion Criteria:

• Ocular hyperemia or other ocular surface findings in either eye

• Active ocular disease

• Current or anticipated use of any topical ocular medication (including artificial tears) during the study

• Intraocular surgery within past six months or unilateral cataract surgery.

• Functionally significant visual field loss

• Anticipated wearing of contact lenses during study

• Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit